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ALDARA (imiquimod cream 5%) recently became avail-
able for the treatment of genital and perianal warts;
however, the topical mechanism of action of imiquimod
is not fully understood. Imiquimod, and its analogs R-
842, S-27609, and S-28463, are potent anti-viral and anti-
tumor agents in animal models. Much of the biologic
activity of these compounds can be attributed to the
induction of cytokines, including interferon-a, tumor
necrosis factor-a, interleukins-1, -6, -8, and others. This
study was performed to characterize the response of mice
and rats to topical application of imiquimod and S-28463
and also to evaluate these agents in cultures of murine and
human skin cells. Topical administration of imiquimod or
S-28463 to the flanks of hairless mice and rats leads to
increases in local concentrations of interferon and tumor
necrosis factor in the skin. The concentrations of inter-
Recently, ALDARA (imiquimod, R-837, or S-26308)5% became available in the U.S.A. for the treatmentof external genital and perianal warts. Imiquimodrepresents the first in a class of immune responsemodifiers that is patient applied. Clinical studies have
demonstrated that imiquimod was significantly more effective than
vehicle (placebo) in clearing genital/perianal warts. In addition, patients
whose target warts cleared tended to remain clear during post-treatment
follow-up periods of up to 12 wk.
The mechanism of action of imiquimod in genital wart patients is
unknown; however, animal studies have shown that imiquimod and
other members of the imidazoquinoline family (R-842, S-27609, and
S-28463) are potent anti-viral and anti-tumor agents (Kende et al,
1988; Harrison et al, 1988, 1991, 1994; Chen et al, 1988; Bernstein
and Harrison, 1989; Sidky et al, 1992; Tomai et al, 1995). These
compounds possess no direct anti-viral or anti-tumor effects; rather,
their activity is mediated in part through the induction of cytokines, in
particular interferon (IFN)-α as demonstrated using IFN-α neutralizing
antibodies (Kende et al, 1988; Sidky et al, 1992). IFN and other
cytokines have been induced by imiquimod and S-28463 in several
species including mice, rats, guinea pigs, monkeys, and humans
following oral administration (Witt et al, 1993; Reiter et al, 1994;
Tomai et al, 1995; Miller et al, 1995).
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feron and tumor necrosis factor were higher at the site
of drug application than in skin from the contralateral
flank or skin from untreated animals. Interferon-a mRNA
levels were also elevated in the skin of mice after topical
application of either imiquimod or S-28463. In vitro, both
imiquimod and S-28463 induced increases in interferon
and tumor necrosis factor in cultures of cells isolated
from hairless mouse skin. Imiquimod also increased
interleukin-8 concentrations in human keratinocyte and
fibroblast cultures, whereas S-28463 induced increases in
tumor necrosis factor in fibroblast cultures. These results
demonstrate that imiquimod and S-28463 stimulate pro-
duction of cytokines in the skin after topical application,
which may play a major role in its activity in genital wart
patients. Key words: immunomodulator/interferon/interleu-
kin/tumor necrosis factor. J Invest Dermatol 110:734–739, 1998
In vitro studies have also shown the importance of cells from the
immune system in the production of these cytokines. Human peripheral
blood mononuclear cell (PBMC) cultures produce IFN-α, tumor
necrosis factor (TNF), interleukin (IL)-1, IL-6, IL-8, and several other
cytokines in response to the imidazoquinolines (Weeks and Gibson,
1993; Tomai et al, 1995; Gibson et al, 1995; Megyeri et al, 1995;
Testerman et al, 1995). In particular, monocyte/macrophages are largely
responsible for the cytokines produced in response to these drugs
(Gibson et al, 1995; Megyeri et al, 1995) and the elevations in cytokines
involve induction of cytokine mRNA and subsequent protein synthesis
(Megyeri et al, 1995; Testerman et al, 1995).
The skin has recently been recognized as an important source of
cytokines with several cells being able to secrete cytokines (Sauder,
1990; McKenzie and Sauder, 1990; VanDamme and Opdenakker,
1990; Katz, 1993; Schroder, 1995). Keratinocytes and dermal fibroblasts
are capable of producing IFN-β, IL-1, IL-6, IL-8, IL-10, and the
colony stimulating factors when exposed to UVB light, mitogens,
lipopolysaccharide (LPS), or other cytokines (VanDamme et al, 1989;
Sauder, 1990; McKenzie and Sauder, 1990; VanDamme and
Opdenakker, 1990; Chodakewitz et al, 1990; Partridge et al, 1991;
Katz, 1993; Swope et al, 1994). Finally, Langerhans cells found in the
epidermis that function as the main antigen presenting cell in the skin,
are also capable of secreting IL-1, IL-6, and TNF-α (Schreiber et al,
1992). These results suggest that cells found in the skin can produce
cytokines if stimulated appropriately.
Imiquimod and S-28463 have been used in an attempt to stimulate
keratinocytes, which are the major cell type found in the epidermis.
Studies have shown that neither imiquimod nor S-28463 were cytotoxic
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in these cultures when tested at concentrations up to 100 µg per ml;
however, cells from the human epidermal keratinocyte cell line,
COLO-16, and normal human keratinocytes produce increased levels
of IL-6 and IL-8 mRNA upon stimulation with imiquimod (Kono
et al, 1994). S-28463 also induced IFN-α, TNF-α, and IL-8 mRNA
as well as TNF and IL-8 protein in these cultures (Fujisawa et al,
1996). These studies indicate the potential of both imiquimod and S-
28463 to activate cells found in the skin.
This study was undertaken to further elucidate the mechanism of
action of imiquimod and S-28463 after topical application. Studies
were performed in both hairless mice and hairless rats evaluating local
cytokine production. In addition, in vitro culture systems were utilized
to further define the cells in the skin that are responding to these
molecules. These are the first studies to demonstrate local production
of IFN and TNF following topical application of imiquimod or S-
28463 to the skin of animals.
MATERIALS AND METHODS
Animals Female hairless SKH-1 mice (6–8 wk of age) and male hairless CD
rats (6–8 wk of age) were purchased from Charles River Labs (Portage, MI).
All protocols using mice and rats were reviewed by the 3M Institutional Animal
Care and Use Committee.
Reagents The compounds imiquimod, 1-(2-methylpropyl)-1H-imidazo-
[4,5-c]quinolin-4-amine, and S-28463, 4-amino-2-ethoxymethyl-α,α-di-
methyl-1H-imidazo[4,5-c]quinoline-1-ethanol, are proprietary molecules of 3M
Pharmaceuticals (St. Paul, MN) and were used as either HCl salts or as free
bases. The structures of these molecules have been described previously (Reiter
et al, 1994; Tomai et al, 1995). For human and mouse cell culture studies, the
HCl salts were dissolved in pyrogen-free water or culture medium and stored
as stock solutions at 4°C for up to 4 mo. For dermal application, the free bases
of imiquimod or S-28463 were dissolved in a cream or gel formulation,
respectively. A stock solution of bacterial LPS from Escherichia coli 055:B5
(Sigma, St. Louis, MO) was dissolved at 1 mg per ml in pyrogen-free water
and stored at 4°C until use.
Polyinosinic:polycytidylic acid (Pharmacia LKB, Milwaukee, WI) was pre-
pared by dissolving the molecule in pyrogen-free water at 56°C for 30 min.
The solution was then allowed to cool to room temperature before use.
Topical studies for local cytokine production A cream formulation of
imiquimod or a gel formulation of S-28463 (10–100 µl) was applied topically
over a 4 cm2 area to the backs or flanks of mice that had been jacketed or of
rats that had been collared to prevent ingestion of the drug. The drug was
applied in 10–100 µl volumes and animals were sacrificed at 1, 2, 4, 6, or 24 h
after treatment. Residual drug was removed using soap and water and then a
200–250 mg skin biopsy was removed from the site of application, snap frozen
in liquid nitrogen, and used for either mRNA isolation or homogenized in
1 ml of RPMI medium containing 10% fetal calf serum (Sigma) for IFN and
TNF protein determination.
mRNA isolation and reverse transcriptase polymerase chain reaction
analysis mRNA was extracted from hairless mouse (SKH-1) skin biopsies
using isolation kits purchased from Invitrogen (San Diego, CA) as previously
described (Testerman et al, 1995). First-strand cDNA was synthesized from
0.1 µg of mRNA using random hexanucelotides (Boeringer Mannheim,
Indianapolis, IN) and reverse transcriptase (Gibco BRL, Gaithersburg, MD),
after which cDNA was amplified using specific primer sets for glyceraldehyde
3-phosphate dehydrogenase (G3PDH), IFN-α, TNF, IL-1α, and IL-6 that
were purchased from Clontech Laboratories (Palo Alto, CA). Sequences of
these primer sets have been published previously (Testerman et al, 1995). The
cDNA was amplified using Taq polymerase (Perkin Elmer, Norwalk, CT) and
dNTP (Pharmacia Milwaukee, WI) in a Perkin Elmer GeneAmp PCR System
9600 (Perkin Elmer) for 30–35 cycles starting initially with a hot start (95°C
for 2 min). The number of cycles was optimized for each primer pair and was
shown to be in the linear range of amplification. Each cycle consisted of
denaturing at 95°C for 15 s, annealing at 55°C for 15 s, and extending for
1 min at 72°C. Products were separated on 1.8% agarose gels and stained with
ethidium bromide (Sigma). Phi X174 DNA digested with HAE III was run in
each gel for molecular weight determinations. Polaroid photographs were taken
of the gels while they were being exposed to UV light and band intensity was
determined from these photographs using a Molecular Dynamics Densitometer
(Sunnydale, CA). To ensure that intensities were in the linear range, dilutions
of the sample were also performed. Areas for cytokine specific bands were
normalized to the G3PDH bands and then multiplied by 100. The data are
presented as the normalized mRNA expression for IFN-α.
Isolation of mouse skin cells Dorsal skin (200 mg) was obtained from 3–
5 female SKH-1 hairless 6–8 wk old mice. The skin was incubated at 37°C
with 100 U collagenase D per ml dissolved in medium for 1 h and then minced.
Fragments were then incubated for an additional hour with 400 U collagenase
D per ml, pressed through a sterile 80 mesh screen with a sterile glass pestle,
and finally rinsed with 100 U collagenase D per ml to obtain a single cell
suspension. The cell suspension was washed twice with phosphate buffered
saline (Celox, Minneapolis, MN) and suspended at 1.5 3 106 cells per ml in
RPMI medium with 10% fetal calf serum, 1% penicillin/streptomycin, and
5 3 10–5 M 2-mercaptoethanol (RPMI complete). Cells were incubated with
various stimuli for 24 h at 37°C.
Cell lines Normal human epidermal keratinocytes, normal human dermal
fibroblasts, and normal human epidermal melanocytes were purchased from
Clonetics (San Diego, CA). Keratinocytes and melanocytes were cultured in
modified MCDB 153 medium containing epidermal growth factor, antibiotics,
insulin, and bovine pituitary extract. Fibroblasts were cultured in MCDB 2020
medium containing basic fibroblast growth factor, insulin, and antibiotics.
Cell culture for cytokine induction Keratinocytes, fibroblasts, and melano-
cyte cultures were grown to 90% confluence in 6 well tissue culture plates
(Falcon, Lincoln Park, NJ). Fresh medium was added and cells were stimulated
with imiquimod, S-28463, or Poly I:C for 24 h at 37°C 1 5% CO2. After
incubation, supernatants were collected, filter sterilized, and stored at –20°C
until cytokine analysis could be performed. Mouse skin cell cultures (1.5 3 106
cells per ml) were incubated in RPMI complete medium for 24 h following
stimulation with imiquimod, S-28463, LPS, or Poly I:C. All cell-free supernat-
ants were collected and stored for cytokine analysis as described below.
Cytokine analysis Mouse IFN was measured by bioassay using mouse L929
cells [American Type Culture Collection (ATCC), Rockville, MD] infected
with encephalomyocarditis virus (ATCC) (Reiter et al, 1994). Human IFN was
measured by bioassay using encephalomyocarditis virus infection of A549
(ATCC) target cells as described previously (Gibson et al, 1995). All other
cytokines were measured by enzyme linked immunosorbent assay (ELISA).
Mouse TNF ELISA kits were purchased from Genzyme (Cambridge, MA).
Mouse IL-6, rat TNF, human TNF, and human IL-6 ELISA kits were purchased
from Biosource (Camarillo, CA). The human IL-1α and IL-8 ELISA kits were
purchased from R&D Systems (Minneapolis, MN).
Statistical analysis Data were analyzed by a Student’s t test. Results were
considered significant only if p , 0.05. Both paired and unpaired tests
were performed.
RESULTS
Cytokine concentrations in mouse and rat skin after topical
application of imiquimod or S-28463 The first set of studies
evaluated IFN and TNF concentrations in the skin after topical
administration of 30 µl of imiquimod cream (5%). Results in Fig 1(a)
show that mean concentrations of IFN (12 U per 20 mg tissue) and
TNF (52 pg per 20 mg tissue) are low in the skin of untreated mice.
One hour after treatment with imiquimod cream, significant induction
of TNF-α is seen at the application site when compared with either
skin from untreated animals or skin from the contralateral flank of the
animal receiving the drug. IFN levels at the drug application site were
also significantly elevated when compared with levels seen from the
contralateral flank that did not receive the drug. At 2 h, both IFN and
TNF concentrations are elevated significantly at the application site.
Results from skin taken 4 h after application indicated significant
increases in IFN and TNF at both sites (data not shown). Application
of vehicle cream showed no significant induction of IFN or TNF
when compared to untreated mice.
Results using topical application of the 1% imiquimod cream are
presented in Fig 1(b). Significant increases in IFN and TNF were seen
at the application site 1 h after treatment. Low levels of IFN and TNF
were again seen in skin from untreated animals. At 2 h after treatment,
mean concentrations of IFN and TNF were significantly higher than
those seen in the contralateral flank as well as those seen in skin from
untreated mice.
S-28463 gel was tested at the 0.01%, 0.1%, and 1% (wt/vol) strengths
for induction of IFN and TNF in the skin of hairless mice (Table I).
Concentrations of TNF and IFN in skin from untreated mice were
similar to those described above. The 0.01% gel formulation showed
only low concentrations of IFN and TNF at the application site.
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Figure 1. Local cytokine levels in the skin of hairless mice following
topical imiquimod application. 5% Imiquimod cream (a) in a 30 µl volume
or 1% imiquimod cream (b) in a 10 µl volume were applied to the backs of
female hairless mice over a 2 cm2 area. At various times after dosing, mice
were sacrificed and a 200 mg skin biopsy was removed at the site of drug
treatment (At) and from a site distant (Away). TNF was measured by ELISA
and IFN was determined by bioassay. Results are presented as the mean of
three animals per point 6 SEM and are expressed as U per 20 mg biopsy for
IFN or pg per 20 mg biopsy for TNF. *Significant difference (p , 0.05) when
compared with the untreated control and when compared with the ‘‘away’’ site.
Table I. TNF and IFN induction in hairless mouse skin by topical S-28463 applicationa
Cytokine concentration per 200 mg biopsy
TNF (pg) IFN (U)
Drug concentration Time (h) At Away At Away
0.01% 0 125 6 25 – 1 6 0.3 –
1 97 6 27 193 6 44 0 0
2 185 6 32 183 6 24 0.9 6 0.6 0
4 192 6 36 187 6 19 1.5 6 0.8 0
0.1% 0 110 6 16 – 0 –
1 146 6 28b,c 113 6 21 2.7 6 1.1 1.6 6 0.7
2 289 6 31c 202 6 29c 239 6 143b,c 1.3 6 0.8
4 330 6 66c 259 6 34c 248 6 104b,c 54 6 37c
1.0% 0 173 6 35 – 2 6 1 –
1 861 6 71b,c 375 6 73c 60 6 20c 56 6 18c
2 1210 6 284b,c 865 6 273c 1691 6 343c 1569 6 459c
4 372 6 154b,c 195 6 100 729 6 486c 498 6 255c
aS-28463 gel (10 µl) was applied to the backs of female mice at 0.01, 0.1, and 1.0% drug concentrations. At various times after dosing, mice were sacrificed and a 200 mg skin biopsy
was removed at the site of drug treatment (AT) and from a site distant (Away). TNF was measured by ELISA and IFN was determined by bioassay with results being presented in pg and
U, respectively. Data are presented as the mean 6 SEM of three mice per point assayed individually.
bSignificant difference (p , 0.05) when compared with the site where the drug was not applied.
cSignificant difference (p , 0.05) when compared with skin from untreated mice.
Significant induction of IFN by the 0.1% strength of S-28463 gel was
seen at the application site 2 and 4 h after dosing. TNF concentrations
were also elevated slightly at all three time points, with the elevation
at 1 h being statistically significant. High concentrations of IFN were
observed after administration of the 1% strength of S-28463 gel;
however, no difference was seen when comparing concentrations at
the site of application and those at the site not receiving the drug. IFN
levels in skin taken from the application site and skin taken from the
contralateral flank were significantly increased when compared with
skin from untreated mice. TNF concentrations at the application site
were significantly higher than those seen in the contralateral flank.
Thus, imiquimod and S-28463, at the strengths tested, were capable
of inducing local cytokine production in the skin following topical
application.
Further studies were performed in hairless rats to determine if the
topical effects of these drugs were limited to mice and to determine if
these drugs were effective topically in animals with thicker skin. In
rats, only TNF was evaluated. Results in Fig 2 demonstrate that the
5% imiquimod cream induced significant increases in TNF concentra-
Figure 2. TNF induction in the skin of hairless rats by topical application
of 5% imiquimod cream. Imiquimod 5% cream (100 µl) was applied to the
right flanks of male rats over a 4 cm2 area. At 2 and 4 h after dosing, rats were
sacrificed and a 200 mg skin biopsy was removed at the site of drug treatment
(At) and from a site on the other flank where drug was not applied (Away).
TNF was measured by ELISA and results are presented in pg per 10 mg biopsy
and represent the mean of six rats per treatment 6 SEM. *Significant difference
(p , 0.05) when compared with the site that did not receive drug and also
with skin taken from untreated rats.
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Figure 3. TNF induction in hairless rat skin by topical application of
0.05% and 0.25% S-28463 gel. S-28463 at 0.05% (a) or 0.25% (b) in a gel
formulation (100 µl) was applied to the right flanks of male rats over a 4 cm2
area. At 2 and 4 h after dosing, rats were sacrificed and a 200 mg skin biopsy
was removed at the site of drug treatment (At) and from a site on the other
flank where drug was not applied (Away). TNF was measured by ELISA with
results being presented in pg per 10 mg biopsy and represent the mean of six
rats per treatment 6 SEM. *Significant difference (p , 0.05) when compared
with the site that did not receive the drug and also compared with skin taken
from untreated rats.
tions at the site of application when compared with skin from untreated
rats and skin taken from the contralateral site. Peak concentrations of
TNF were seen at 4 h. Serum concentrations of TNF were evaluated
and no elevations were seen after drug application.
S-28463 gel at either the 0.05 or the 0.25% strength was also tested
for local TNF induction in hairless rats. Results in Fig 3 present the
data for both the 0.05% (Fig 3a) and the 0.25% (Fig 3b) gel formulations
of S-28463. Skin from animals receiving the 0.05% strength of S-
28463 had significantly higher levels of TNF at the application site
when compared with skin from either the contralateral flank or the
untreated rats. These elevations were seen at both 2 and 4 h. Similar
results were seen when applying the 0.25% gel strength. Significant
elevations in TNF (2 and 4 h) were seen with peak concentrations at
2 h. No differences were seen between skin taken from untreated rats
and skin taken from the untreated sites of animals that had been dosed.
Finally, neither the 0.05 nor the 0.25% formulation of S-28463
increased TNF concentrations in the serum. These results demonstrate
that topical application of either imiquimod or S-28463 to the skin of
animals leads to increased cytokine production at the site of application.
Induction of IFN-a mRNA in mouse skin after topical drug
treatment To determine whether the induction of IFN was through
activation of local transcription or not, imiquimod cream 5% and S-
Figure 4. Induction of IFN-a mRNA in mouse skin after topical
application of imiquimod 5% cream or S-28463 1% gel. 5% Imiquimod
cream (100 µl) or 1% S-28463 gel (100 µl) was applied to the backs of female
hairless mice over a 2 cm2 area. At various times after dosing, mice were
sacrificed, skin was removed, and mRNA was isolated and subjected to reverse
transcriptase polymerase chain reaction. Products were separated by agarose gel
electrophoresis and band intensity was quantitated by densitometry. IFN band
intensity was normalized to the house keeping gene, G3PDH, to control for
differences in starting amounts of mRNA, and multiplied by 100. Results are
presented as the mean 6 SEM of three individual experiments. *p , 0.05
when compared with the 0 h sample.
28463 gel 1% were applied to the skin of hairless mice and mRNA
was semiquantitated by reverse transcriptase polymerase chain reaction.
Application of imiquimod caused a significant increase in IFN-α
mRNA at 4 h after administration when compared with untreated
animals (Fig 4). The 1 and 2 h samples also showed an increase in
mRNA for IFN-α, although this was not statistically significant. At 6
and 24 h, the mRNA levels for IFN-α were similar to control levels.
mRNA levels for TNF were not significantly elevated in skin receiving
topical imiquimod (data not shown).
S-28463 gel 1% also significantly increased IFN-α mRNA levels,
compared with skin from untreated mice, at 2 and 4 h after a single
application. In addition, there was an increase in mRNA at the 1 and
6 h time points; however, these were not statistically significant. IFN-
α mRNA levels had returned to control levels in the samples taken
24 h after application. Induction of IFN-α mRNA was also noted
using the 0.1% strength of S-28463 gel (data not shown). Cytokine
specific mRNA for TNF was also evaluated after a single administration
of S-28463 with no induction noted when compared with the placebo
control. Thus, topical application of imiquimod or S-28463 leads to
increased IFN-α mRNA levels that are responsible for the increase
in protein.
Cytokine induction in isolated mouse skin cell preparations and
human keratinocyte, fibroblast, and melanocyte cultures Because
there are several cell types in the skin that are able to produce cytokines,
it was important to evaluate in vitro the cells from skin that may be
responsible for the cytokines produced after topical drug treatment.
Results of cytokine induction in unseparated mouse skin cell prepara-
tions are presented in Fig 5. Control cultures receiving medium alone
had relatively high concentrations of both IFN and TNF when
compared with cultures of cells from either spleen or bone marrow.
Imiquimod induced increased IFN levels above untreated control
cultures at both 3 and 1 µg per ml but did not increase TNF levels at
either concentration tested. S-28463 showed significant induction of
both IFN and TNF at 1 µg per ml when compared with untreated
control cultures. LPS induced a statistically significant increase in IFN
and TNF concentrations. Poly I:C induced significant increases in IFN
production without significantly increasing TNF production. These
studies indicate that cells isolated from the skin are capable of secreting
increased concentrations of both IFN and TNF in response to
imiquimod or S-28463.
Several isolated human cell preparations including keratinocytes,
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Figure 5. Cytokine induction in mouse skin cell preparations by
imiquimod and S-28463. Mouse skin cells (1.5 3 106 per ml) were stimulated
for 24 h with imiquimod (Imiq), S-28463 (463), LPS, or Poly I:C. Cell free
supernatants were collected for cytokine analysis. The data are presented as the
mean 6 SEM from three to seven experiments. *Statistically significant
difference (p , 0.05) when compared with the untreated control cultures.
fibroblasts, and melanocytes were evaluated for cytokine production
in response to imiquimod and S-28463. These drugs were not cytotoxic
for any of these cell types at concentrations up to 100 µg per ml.
Imiquimod, but not S-28463, was effective at stimulating significantly
increased production in IL-8 concentrations in keratinocyte cultures
(2 pg per ml in untreated cultures versus 28 pg per ml in imiquimod
treated cultures). IFN, IL-1, IL-6, and TNF were not increased by
either imiquimod or S-28463. In fibroblast cultures, imiquimod was
again able to significantly increase IL-8 concentrations 2-fold over
background, whereas S-28463 significantly increased TNF concentra-
tions (2–3-fold). No significant increases were seen in IFN, IL-1,
or IL-8 concentrations in fibroblast cultures stimulated with either
compound. Finally, neither imiquimod nor S-28463 caused any increase
in IFN, IL-1, IL-6, IL-8, or TNF concentrations in melanocytes.
DISCUSSION
Although imiquimod cream 5% has recently become available for the
treatment of external genital and perianal warts, the mechanism of
action is not fully understood. Most of the mechanistic studies reported
thus far have focused on systemic routes of application or in vitro studies
using immunocompetent cell populations. This study focused on
cytokine induction by imiquimod and the more potent analog S-
28463 after topical application to skin. Results reported herein extend
previous findings by demonstrating local production of cytokines in
the skin following topical application. Local cytokine production by
topical application of these agents was demonstrated in both mice and
rats, indicating that this result is not species specific.
The kinetics of cytokine induction following topical application of
these drugs occurs within hours. Similar kinetics for induction of IFN
and TNF were seen between imiquimod and S-28463 when evaluated
in mice. The kinetics are shifted slightly to the right when compared
with kinetics seen after systemic dosing of mice with these compounds,
which may be due to slightly slower absorption by the topical route
(Miller et al, 1995). In rats, peak concentrations of TNF are seen
slightly earlier for S-28463 gel when compared with imiquimod cream.
One possible explanation is that S-28463 gel is able to penetrate rat
skin more effectively. IFN was not evaluated in rat samples due to
toxicity of the skin homogenates in the rat IFN bioassay. With regard
to potency, S-28463 was active at strengths of 0.05% and above,
whereas imiquimod was active at strengths only above 1%, indicating
that S-28463 was at least 20-fold more potent in this topical model.
Similar results have been observed using systemic administration of the
drug as well as in vitro studies (Tomai et al, 1995). The kinetics of
cytokine induction after topical application of the drug suggests that
induction is rapid and is likely through activation of cells already
present in the skin.
The induction of cytokines in the skin by imiquimod and S-28463
appears to be due to local stimulation. In both mice and rats,
concentrations at the application site were almost always higher than
those seen when skin was taken from the flank that did not receive
the drug or from untreated animals. Also, in hairless rats there was no
increase in serum concentrations of TNF following topical application
of either drug. In mice treated with high strengths of S-28463 (1.0%),
IFN and TNF were seen at both biopsy sites leading to the possibility
that some of the drug may be reaching the systemic circulation.
Alternatively, the cytokines seen at the site where the drug was not
applied could be a result of locally produced cytokine entering the
systemic circulation. Studies are in progress to define which hypothesis
is correct. These results indicate that the topical application leads to
local production of cytokines without generating a systemic response.
The induction of local cytokines by these drugs is probably due to
increases in transcription, because increases in IFN-α mRNA were
also seen in skin from drug treated animals. The kinetics of induction
of IFN-α mRNA indicated increases as early as 1 h after dosing with
levels returning to background by 6–24 h. The increases in mRNA
for IFN-α correlated quite well with the kinetics for detection of the
protein. These results again indicate that these drugs activate cells in
the skin to produce IFN, specifically IFN-α.
The inability to detect increases in TNF mRNA was surprising;
however, it may be that earlier sampling was necessary to detect
increases in this mRNA. It is possible that the polymerase chain
reaction technique used may not be able to detect subtle differences
in mRNA levels or that the increases in TNF may be due to the
release of stored protein, as is seen with mast cells (Gordon and Galli,
1991); however, this latter possibility seems unlikely because mRNA
and protein synthesis are required for cytokine induction by imiquimod
and S-28463 in other systems (Testerman et al, 1995).
Studies have shown that cells of the monocyte/macrophage lineage
are capable of producing cytokines in response to the imidazoquinolines
(Tomai et al, 1995; Gibson et al, 1995; Megyeri et al, 1995; Testerman
et al, 1995). In vitro results using cells isolated from mouse skin correlate
well with the results obtained in vivo following topical application of
the drug. Studies using cultures of mouse skin cells showed increases
in IFN and TNF in response to these drugs. One problem with this
system was the high concentrations of IFN and TNF seen in the
control cultures. This was most likely a result of the isolation procedure.
S-28463, but not imiquimod, was effective at increasing production
of TNF in these cultures. This is not surprising because imiquimod is
fairly ineffective at inducing TNF in human PBMC (Testerman et al,
1995). These results indicate that cells in the skin are capable of
secreting cytokines in response to either imiquimod or S-28463.
Previous studies by Sauder et al have shown increases in cytokine
specific mRNA for human keratinocyte cultures with imiquimod or
S-28463 (Kono et al, 1994; Fujisawa et al, 1996). Imiquimod only
stimulated increases in IL-8 concentrations in keratinocyte cultures,
whereas S-28463 was ineffective at stimulating any of the cytokines
evaluated. There may be several explanations as to why the results in
this study did not correlate with the results obtained by Sauder et al.
It is possible that the mRNA for IL-6 and IL-8 was not translated into
protein, or that the ELISA used to measure IL-6 and IL-8 concentrations
were not sensitive enough to detect the small differences in cytokine
concentrations that may be present. Finally, it may be that the cytokines
were quickly bound to cytokine receptors or that receptors for these
cytokines are induced by these drugs. The inability to detect induction
of cytokines by imiquimod or S-28463 is not due to an inability of
keratinocytes to make cytokines, because Poly I:C was very effective
at stimulating these cells to produce cytokines.
Results from this study also show that fibroblasts are poor responders
to both imiquimod and S-28463. Increases in IL-8 were seen following
imiquimod stimulation and increases in TNF were seen following S-
28463 stimulation. These elevations were minimal when compared
with Poly I:C, which was very effective at inducing IFN, IL-6, and
IL-8 in these cultures. Published results using Poly I:C have also shown
induction of IFN-β, IL-6, and IL-8 in fibroblast cultures (VanDamme
et al, 1989; VanDamme and Opdenakker, 1990). These results suggest
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that, if stimulated properly, keratinocytes and fibroblasts can secrete
high levels of IFN and several proinflammatory cytokines.
Other cell types found in the skin, such as Langerhans cells and
dermal macrophages, are known to secrete cytokines. Langerhans cells,
the major antigen presenting cells in the epidermis, as well as the
dermal macrophage, may be major contributors to the response seen
after topical application of these drugs. Studies using enriched dendritic
populations suggest that these cells do respond by producing cytokines
to imiquimod and S-28463 (personal observation). These cells may
play a prominent role in the initial response to imiquimod and S-
28463 following topical application.
In conclusion, the results described in this study demonstrate that
both imiquimod and the more potent analog S-28463 are capable of
inducing local production of IFN and TNF following topical applica-
tion. Local induction of these cytokines in the skin may play an
important role in the efficacy of imiquimod in the treatment of external
genital and perianal warts, and may suggest other possible topical
disease targets that may benefit from this therapy.
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